Expert: Combination of Lenvatinib, Pembrolizumab Outperformed Sunitinib in the Treatment of Advanced RCC
Viktor Grunwald, MD, PhD, discusses the post-hoc analysis of the phase 3 CLEAR trial investigating the combination treatment in the first-line setting for advanced renal cell carcinoma.
Source: pharmacytimes.com